uniQure N.V

Financials

Gesamtvermögen 556.54 M605.4 M584.89 M888.38 M824.91 M Gesamtverbindlichkeiten 563.29 M571.72 M588.89 M659.64 M626.01 M Gesamtkapital -6.75 M33.69 M-4 M228.75 M198.9 M Gesamtverbindlichkeiten und Eigenkapital 556.54 M605.4 M584.89 M888.38 M824.91 M Gesamtverschuldung 51.32 M51.59 M51.84 M51.88 M49.7 M Nettoverschuldung -316.36 M-357.43 M-325.3 M-642.42 M-573.15 M

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

QURE

Financials

uniQure N.V

Nachrichten

Nurix Therapeutics (NRIX) Moves 6.9% Higher: Will This Strength Last?

uniQure Investors Sue Company Over Huntington’s Disease Drug Study Claims - TipRanks.com

Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?

PGIM Jennison Health Sciences Fund Q4 2025 Key Contributors And Detractors

A Unique Situation For UniQure (QURE)

Führungswechsel bei der FDA: Mizuho stuft uniQure-Aktie auf "Outperform" hoch

Mizuho upgrades uniQure stock rating on FDA leadership change

Avago, Lumentum among market cap stock movers on Monday

uniQure: Chardan erhöht Kursziel nach Personalwechsel bei der FDA

Chardan raises uniQure stock price target on FDA leadership change

Tesla and Facebook among market cap stock movers on Monday

Biotech Stocks Pop After CBER Chief Exit - Moderna (NASDAQ:MRNA)